Skip to content
value.today

Aspargo Laboratories, Inc.

Formerly VirgaTech, Inc.

Total raised
$12 M
3 rounds on record
Latest round
$2 M
Mar 2022
First round on record
Feb 2020
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Aspargo Laboratories, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2022$2 MNo. 3Under $2 million

Aspargo Laboratories, Inc.: Raise no. 3, Mar 2022

Investors in this round

19 investors had bought by the notice of Mar 28, 2022: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $60 M offered; $58 M still to sell
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$91,920
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Demurjian · Executive Officer, Director, Promoter
  • Fred Biehl · Director
  • Michael Rice · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Newbridge Securities Corporation (CRD 130814) · Boca Raton, FloridaSold in FL, MA, MD, NJ, NY, PA, SC, TX, WA

Signed by Michael Demurjian, Ceo. Source: SEC Form D, newest notice filed Mar 28, 2022. Read the notice at the SEC.

equitySEC
Feb 2020$3 MNo. 2$2 to $10 million

Aspargo Laboratories, Inc.: Raise no. 2, Feb 2020

Investors in this round

88 investors had bought by the notice of Jul 28, 2020: 88 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $9 M offered; $6 M still to sell
Smallest investment taken
$5,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$700
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Demurjian · Executive Officer, Director, Promoter · Founder of the Company.
  • Fred Biehl · Director
  • Michael Rice · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • David Sukoff (CRD 4232120) · broker-dealer Arq Advisors LLC (CRD 289499) · Summit, New JerseySold in CA, CO, FL, MA, MD, NC, NH, NJ, NY, OH, PA, SC, VT, WV

Remarks in the notice

  • On fees: “Sales commissions amount reflects amount due as of filing date of this Amendment for recently engaged placement agent. Estimated future commissions is contingent on sales volume.”
  • On the use of proceeds: “The Company is virtual. All executive officers and directors serve without compensation.”

Signed by Michael Demurjian, Chairman and CEO. Source: SEC Form D, newest notice filed Jul 28, 2020. Read the notice at the SEC.

equitySEC
Feb 2020$8 MNo. 1$2 to $10 million

Aspargo Laboratories, Inc.: Raise no. 1, Feb 2020

Investors in this round

290 investors had bought by the notice of Oct 15, 2020: 290 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $9 M offered; $1 M still to sell
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$16,660
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Demurjian · Executive Officer, Director, Promoter
  • Fred Biehl · Director
  • Michael Rice · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Arq Advisors (CRD 289499) · broker-dealer David Sukoff (CRD 4232120) · Summit, New JerseySold in NJ, NY
  • Eagles Coast Capital (CRD 297477) · Mount Pleasant, South CarolinaSold in NC, SC

Signed by Michael Demurjian, Ceo. Source: SEC Form D, newest notice filed Oct 15, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Aspargo Laboratories, Inc. had no revenue when it filed its newest notice of a funding round (Mar 2022).

    SEC Form D (revenue range) · Mar 2022

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2022

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Aspargo Laboratories, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 290 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Aspargo Laboratories, Inc.
NameRoleNamed in
Michael DemurjianExecutive officerMar 2022
Fred BiehlDirectorMar 2022
Michael DemurjianDirectorMar 2022
Michael RiceDirectorMar 2022
Michael DemurjianPromoterMar 2022